World Journal of Pharmaceutical and Life Sciences

www.wjpls.org

Impact Factor: 8.21 Coden USA: WJPLA7

ARTEMISININ FROM *ARTEMISIA ANNUA*: A COMPREHENSIVE REVIEW OF ITS ANTIMALARIAL POTENTIAL

Dr. Alinda Thomaseena*[1], M. Ramya[2], A. Yamuna[3], M. Suresh[4]

[1]Assistant Professor, Department of Pharmacognosy, G.P. Pharmacy College, Jolarpet, Tirupattur, Tamil Nadu, India.
[2,3,4]Department of Pharmacy, G.P. Pharmacy College, Jolarpet, Tirupattur, Tamil Nadu, India.

***Corresponding Author: Dr. Alinda Thomaseena**

Assistant Professor, Department of Pharmacognosy, G.P. Pharmacy College, Jolarpet, Tirupattur, Tamil Nadu, India. **DOI:** https://doi.org/10.5281/zenodo.21715623

How to cite this Article: Dr. Alinda Thomaseena*[1], M. Ramya[2], A. Yamuna[3], M. Suresh[4] (2026). Artemisinin From *Artemisia Annua*: A Comprehensive Review Of Its Antimalarial Potential. World Journal of Pharmaceutical and Life Sciences, 12(8), 45–59.

Article Received on 03/07/2026 **Article Revised on 24/07/2026** **Article Published on 01/08/2026**

ABSTRACT

Malaria remains one of the world's most serious infectious illnesses, producing major morbidity and mortality, particularly in tropical and subtropical areas. The rise of drug-resistant Plasmodium variants has highlighted the urgent need for effective and safe antimalarial medicines. Artemisinin, a sesquiterpene lactone derived from Artemisia annua L., has transformed malaria treatment with its quick and powerful antimalarial effect. The purpose of this review is to provide a complete understanding of artemisinin's botanical profile, phytochemistry, pharmacological activities, mechanism of action, therapeutic applications, safety profile, and future prospects. The review focuses on artemisinin's unique endoperoxide bridge, which is critical in producing reactive oxygen species and triggering parasite death. In addition to its known antimalarial activity, artemisinin has antioxidant, anti-inflammatory, anticancer, and immunomodulatory characteristics, indicating a broad therapeutic potential. Artemisinin derivatives and artemisinin-based combination medicines have considerably improved malaria treatment and contributed to worldwide malaria control efforts. However, issues such as increasing artemisinin resistance and sustainable manufacturing continue to need attention. Overall, artemisinin remains a vital natural-product-derived medication and exemplifies medicinal plants' contribution to modern medicine. Continued research is required to improve therapeutic applications and address future problems in malaria treatment.

KEYWORDS: *Artemisia annua*, Artemisinin, Malaria, Antimalarial Activity, Phytochemistry, Artemisinin-Based Combination Therapy, Medicinal Plants.

1. INTRODUCTION

1.1 Overview of Malaria

Malaria is an infectious disease transmitted by mosquitos and caused by Plasmodium parasites.[1] It remains one of the most serious parasite illnesses infecting people and a major public health concern in many tropical and subtropical regions around the world. The disease is spread through the bite of an infected female Anopheles mosquito, which introduces the parasite's infective stage into the human bloodstream. For ages, malaria has been recognized as a leading cause of sickness and death, particularly in developing nations where disease transmission is facilitated by environmental and socioeconomic factors.[1]

Humans can be infected by five Plasmodium species: Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium knowlesi. P. falciparum is the most virulent species, accounting for most severe malaria cases and deaths globally. The parasite has a complex life cycle that includes both mosquito and human hosts. Following transmission, the parasite multiplies in liver cells before infecting red blood cells, where recurrent replication cycles cause the disease's hallmark clinical signs.[2]

Malaria's clinical appearance ranges from mild to severe, depending on the infecting species, parasite burden, host immunity, and access to medical care. Common symptoms include fever, chills, headache, perspiration, exhaustion, nausea, and muscle discomfort. In extreme cases, consequences can include cerebral malaria, severe

anemia, acute respiratory distress syndrome, metabolic acidosis, kidney failure, and multiple organ dysfunction. Severe malaria can quickly lead to death if not diagnosed and treated promptly.

Despite great breakthroughs in malaria prevention and management, the disease continues to have a significant health and economic impact on endemic countries. The emergence and spread of antimalarial drug resistance has exacerbated illness management and emphasized the critical need for new treatment medicines. The discovery of artemisinin from Artemisia annua marked a watershed moment in antimalarial drug research, greatly improving treatment outcomes for malaria patients.[3]



Figure 1: Life Cycle of the Malaria Parasite.

1.2 Global Burden of Malaria

Malaria is a major public health concern, especially in tropical and subtropical climates.[4] Despite significant advances made through vector control efforts, improved diagnostic tools, and potent antimalarial medicines, malaria still affects millions of people each year. Poverty, inadequate healthcare facilities, poor sanitation, and environmental circumstances conducive to mosquito reproduction all contribute to the disease's persistence in many developing countries.

Malaria affects people differently around the world, with Sub-Saharan Africa having the highest frequency. This region is responsible for the bulk of malaria cases and deaths due to the widespread presence of Plasmodium falciparum, the most aggressive malaria parasite. Children under the age of five, pregnant women, immunocompromised individuals, and people living in isolated locations are most vulnerable to severe illness and malaria-related death. Malaria is still endemic throughout Asia, Latin America, and Oceania, where it continues to have an impact on population health and economic output.

Malaria not only has medical repercussions but also has a significant socioeconomic impact on affected countries.[5] The condition increases healthcare costs, lowers workforce productivity, reduces school attendance, and slows economic growth. Families frequently face financial difficulties because of medical expenses and loss of income during illness. Malaria has a severe impact on national healthcare systems and restricts socioeconomic development, particularly in resource-constrained environments.

The persistent global burden of malaria emphasizes the need for effective prevention and treatment techniques. The use of artemisinin-based combination treatments (ACTs) has dramatically improved treatment outcomes and reduced malaria-related fatalities in many endemic areas. Nonetheless, growing drug resistance, climate change, and population movement continue to endanger malaria control efforts, underlining the need for long-term research and innovation in anti-malarial drug

development.

1.3 History of Antimalarial Drug Discovery

The hunt for effective antimalarial medicines has a long and impressive history that dates back millennia. Prior to the introduction of modern medicine, traditional herbal treatments were frequently utilized to treat febrile diseases caused by malaria. The discovery of quinine from the bark of Cinchona species, a medicinal plant native to South America,[6] marked a significant breakthrough in antimalarial therapy. Quinine was the first effective treatment for malaria and remained the primary antimalarial drug for years.

During the twentieth century, significant attempts were made to develop synthetic antimalarial medicines to overcome the limits of natural drugs. This resulted in the introduction of various medications, including chloroquine, primaquine, pyrimethamine, sulfadoxine, and mefloquine. Chloroquine became the most used antimalarial agent due to its efficacy, low cost, and excellent safety profile. For decades, chloroquine was a key component of global malaria control operations, helping to drastically reduce malaria-related morbidity and mortality.

However, continuous usage of antimalarial medications led to the creation of drug-resistant forms of Plasmodium falciparum.[7] Resistance to chloroquine and other conventional antimalarial medicines developed gradually throughout endemic areas, lowering treatment efficacy and posing a significant challenge to malaria control efforts. The growing incidence of resistant parasites has underlined the critical need for new antimalarial drugs with novel modes of action.

Artemisinin from Artemisia annua, a medicinal plant historically used in Chinese medicine, was discovered in the 1970s, marking a significant advance. Artemisinin exhibited quick and robust antimalarial action against Plasmodium isolates that were both medication-sensitive and treatment resistant. The subsequent invention of artemisinin derivatives and artemisinin-based combination treatments (ACTs) transformed malaria treatment and remains one of the most significant advances in antimalarial drug research. ACTs are now the standard treatment for uncomplicated P. falciparum malaria in many regions of the world.

1.4 Need for New Antimalarial Agents

Developing novel antimalarial drugs is crucial given the global malaria incidence and limitations with current treatment options. Although traditional antimalarial medications have played an important role in lowering disease incidence and death, their efficacy has been jeopardized by the introduction and spread of drug-resistant Plasmodium species. Resistance to routinely used medications such as chloroquine, sulfadoxine-pyrimethamine, and, in some areas, lower susceptibility to artemisinin-based regimens has complicated malaria management and underlined the importance of ongoing drug discovery efforts.[8]

Another key worry is malaria parasites' capacity to quickly adjust to treatment pressure. Genetic alterations in parasite populations can lower drug sensitivity, resulting in treatment failure and the spread of resistant strains. Resistance not only restricts the efficacy of existing medications, but it also raises healthcare expenditures and increases the risk of serious illness complications. As a result, the discovery of new molecules with distinct modes of action remains a top focus in antimalarial research.

In addition to drug resistance, several currently available antimalarial medicines have limitations such as side effects, low patient compliance, extensive treatment regimens, and limited efficacy against specific phases of the parasite life cycle. These problems highlight the need for safer, more effective, and less expensive therapeutic approaches that can eliminate parasites quickly while limiting toxicity and resistance development.

Natural products continue to be a major source of new therapeutic leads in malaria research. The success of quinine and artemisinin indicates medicinal plants' crucial role in the creation of potent antimalarial medicines. Ongoing research into plant-derived chemicals and derivatives may help to produce next-generation antimalarial medicines that can meet present and future malaria control issues.

1.5 Introduction to Artemisinin

Artemisinin is a sesquiterpene lactone endoperoxide chemical found in Artemisia annua L., sometimes known as sweet wormwood or Qinghao.[9] It is considered one of the most significant discoveries in the history of antimalarial drug development due to its powerful and quick effectiveness against Plasmodium parasites. The molecule was found during a large-scale Chinese research program targeted at developing effective malaria therapies, particularly against drug-resistant forms, which had become a serious public health concern.

Artemisia annua's therapeutic use dates to traditional Chinese medicine, when the plant was used to treat fever-related disorders. Scientific examination of this traditional treatment resulted in the isolation of artemisinin and the discovery of its outstanding antimalarial effects. Unlike traditional antimalarial medications, artemisinin has a unique chemical structure characterized by an endoperoxide bridge, which is crucial for its biological activity and contributes to its fast parasite-killing effect.

Artemisinin has broad-spectrum activity against several stages of the malaria parasite, although it is especially effective against Plasmodium falciparum, even drug-resistant variants. Following its discovery, various semisynthetic derivatives, including artesunate,

artemether, dihydroartemisinin, and artemether, were created to improve pharmacokinetic qualities and therapeutic efficacy. These derivatives represent the foundation of artemisinin-based combination treatments (ACTs), which are now the preferred first-line treatment for uncomplicated malaria in many endemic areas.

The success of artemisinin demonstrates the value of medicinal plants as sources of bioactive chemicals for drug discovery. Its discovery not only transformed malaria treatment but also demonstrated the relevance of pharmacognosy in uncovering natural compounds with great medicinal promise. Artemisinin and its derivatives are still essential components of global malaria control programs, and they are the subject of intensive pharmacological and clinical study.



Figure 2: Discovery and Development of Artemisinin from *Artemisia annua.*

2. BOTANICAL PROFILE OF *Artemisia annua*

2.1 Taxonomical Classification of *Artemisia annua*

Artemisia annua L., sometimes known as sweet wormwood, annual wormwood, or Qinghao, is a fragrant medicinal plant belonging to the Asteraceae.[10] The plant is well-known as a natural source of artemisinin, a sesquiterpene lactone that has revolutionized malaria treatment. Because of its tremendous pharmacological value, A. annua has become one of the most thoroughly investigated medicinal plants in the fields of pharmacognosy and natural product research.

A. annua is classified as part of the Artemisia genus, which includes over 500 species found throughout the world's temperate climates. The plant is an annual herb known for its tall growth pattern, aromatic leaves, and little yellow flowers. It is native to China, but it is now grown in several countries for the commercial production of artemisinin and other phytochemicals.

The accurate taxonomical classification of Artemisia annua is critical for botanical identification, cultivation methods, phytochemical research, and herbal material quality control. Accurate classification also promotes research into the plant's medicinal characteristics and therapeutic applications.

Table 1: Taxonomical Classification of *Artemisia annua.*

Taxonomic Rank	Classification
Kingdom	Plantae
Division	Magnoliophyta
Class	Magnoliopsida
Order	Asterales
Family	Asteraceae
Genus	*Artemisia*
Species	*Artemisia annua* L.

2.2 Morphological Characteristics of *Artemisia annua*

Artemisia annua, an annual aromatic plant, can reach a height of 0.5-3.0 meters under good conditions.[11] The plant has a well-developed taproot system and an upright, highly branching stem that is cylindrical, grooved, and green to reddish-brown in colour. Because of the presence of glandular trichomes on its aerial

portions, the plant has a distinct aromatic odour.

A. annua has alternating, deeply split leaves that appear bright green. The lower leaves are larger and petiolate, while the upper leaves are smaller and sessile. The finely dissected leaf structure enhances the available surface area for the formation of glandular trichomes, which are the principal sites of artemisinin biosynthesis and storage.

The plant produces numerous little yellow blooms that are grouped in loose panicles. Each flower head is spherical and contains both ray and disc florets. Flowering usually happens in late summer or falls, depending on the environmental circumstances and geographical location. Following fertilization, the plant produces little seeds for multiplication and cultivation.

Morphological identification of Artemisia annua is critical for effective plant authenticity and quality control in medicinal plant research. Plant height, leaf morphology, branching pattern, floral structure, and fragrant nature are major distinguishing factors between A. annua and other Artemisia species.



Figure 3: Morphological Features of *Artemisia annua.*

2.3 Geographical Distribution and Cultivation of *Artemisia annua*

Artemisia annua, a native of China, has been used for ages as a medicinal plant due to its therapeutic properties.[12] Because of the growing global demand for artemisinin, the plant is currently grown in several nations including Asia, Africa, Europe, North and South America. China, Vietnam, India, Kenya, Tanzania, Uganda, Madagascar, Brazil, and Eastern Europe are among the most important agricultural regions. The plant's capacity to adapt to a variety of environmental conditions has permitted extensive cultivation for commercial artemisinin production.

Climate and geography have a considerable influence on A. annua's growth and output. The plant thrives in temperate and subtropical areas with moderate rainfall, enough sunlight, and well-drained, fertile soils. Optimal growth is often found at temperatures ranging from 20°C to 30°C. Environmental factors such as altitude, photoperiod, soil fertility, and irrigation practices have a major impact on plant biomass and artemisinin concentration.

Commercial cultivation of A. annua has grown in relevance as malaria treatment relies more heavily on artemisinin-based combination treatments (ACTs). Agricultural procedures such as seed selection, nursery management, transplantation, fertilization, and harvesting are meticulously tuned to increase artemisinin yield. Harvesting is normally done during the flowering period, when the concentration of artemisinin in the

aerial portion's peaks.

The global cultivation of Artemisia annua is critical to guaranteeing a steady supply of artemisinin for pharmaceutical manufacture. Continued research into new cultivars, cultivation techniques, and agronomic practices is critical for increasing output and meeting the growing demand for antimalarial medications generated from this medicinal plant.



Figure 4: Global Distribution and Cultivation Regions of *Artemisia annua.*

3. PHYTOCHEMISTRY OF *Artemisia annua*

3.1 Overview of Phytochemical Constituents

Artemisia annua contains potent compounds that enhance its medicinal and pharmacological properties.[13] The plant includes a wide variety of secondary metabolites, including sesquiterpenes, flavonoids, coumarins, phenolic acids, essential oils, and bioactive chemicals. Artemisinin is the most important of these elements due to its powerful antimalarial activity and therapeutic value.

A. annua's phytochemical composition changes according to genetic factors, geographic location, meteorological conditions, production strategies, and harvesting time. The aerial parts of the plant, namely the leaves and flowering tops, have the highest concentration of bioactive compounds. Numerous investigations have shown that these phytochemicals have not only antimalarial activity, but also antioxidant, anti-inflammatory, antibacterial, anticancer, and immunomodulatory effects.

Artemisinin is characterized as a sesquiterpene lactone with a distinct endoperoxide bridge that is responsible for its antimalarial properties. In addition to artemisinin, the plant contains many flavonoids, including quercetin, luteolin, kaempferol, and casticin, which may boost artemisinin's biological activity via synergistic interactions. The plant contains essential oils such as camphor, 1,8-cineole, artemisia ketone, and β-caryophyllene, which contribute to its unique aroma and therapeutic properties.

Artemisia annua's complex phytochemical profile has piqued scientists' curiosity, and research into potential medicinal compounds derived from natural sources continues. Understanding the phytochemical components of the plant is critical for quality control, standardization, and optimization of artemisinin production.[13]



Figure 5: Major Phytochemical Constituents of *Artemisia annua.*

3.2 Artemisinin: Structure and Chemical Properties

Artemisinin, the main bioactive component of Artemisia annua, is responsible for the plant's strong antimalarial properties.[14] Chemically, artemisinin is a sesquiterpene lactone with a distinct endoperoxide bridge that sets it apart from other naturally occurring molecules.

This peroxide connection is thought to be critical for its pharmacological activity, which plays an important part in the elimination of malaria parasites.

Artemisinin's chemical formula is $C_{15}H_{22}O_5$, with a molecular weight of approximately 282.33 g/mol. The molecule appears as a colorless crystalline solid with poor solubility in water but high solubility in organic solvents like ethanol, chloroform, and acetone. Due to its low water solubility and short biological half-life, various semisynthetic derivatives have been created to improve its pharmacokinetic characteristics and therapeutic efficacy.

Artemisinin's antimalarial activity is mostly due to the cleavage of its endoperoxide bridge in the presence of iron in infected erythrocytes. This process produces reactive oxygen species and free radicals, which damage critical proteins and cellular components of the malaria parasite, resulting in fast parasite death. Its unique method of action makes it effective against both drug-sensitive and drug-resistant Plasmodium strains.[14]

The unique chemical structure of artemisinin has piqued scientists' interest and served as the foundation for the invention of various clinically relevant derivatives, including artesunate, artemether, dihydroartemisinin, and arteether. These compounds continue to play an important part in modern antimalarial therapy and are one of the most successful examples of natural-product drug discovery.



Figure 6: Chemical Structure of Artemisinin Showing the Endoperoxide Bridge.

3.3 Artemisinin Derivatives

Artemisinin has good antimalarial action, but its clinical use is limited due to poor water solubility, low bioavailability, and short plasma half-life.[15] To address these restrictions, numerous semisynthetic derivatives have been produced. These compounds improve pharmacokinetic features while keeping the original compound's robust antimalarial action. The creation of these derivatives greatly increased artemisinin's therapeutic utility and led to the success of modern malaria treatment tactics.

The most important derivatives include artesunate, artemether, dihydroartemisinin, and arteether. Artesunate is a water-soluble derivative that can be given orally, intravenously, intramuscularly, or rectally, making it very effective in severe malaria. Artemether and arteether are lipid-soluble derivatives that have better absorption and longer action. Dihydroartemisinin, an active metabolite of various artemisinin derivatives, has significant antimalarial activity against both asexual blood stages and early gametocytes of Plasmodium parasites.

These compounds work similarly to artemisinin, activating the endoperoxide bridge with iron released from haemoglobin digestion within infected erythrocytes. The resultant free radicals cause significant damage to parasite proteins, membranes, and metabolic pathways, resulting in fast parasite elimination. Their rapid onset of action makes them very useful in lowering parasite burden and averting severe disease development.

The introduction of artemisinin derivatives transformed malaria treatment globally. They are currently utilized in artemisinin-based combination treatments (ACTs), which mix them with longer-acting partner medicines to increase therapeutic efficacy and delay resistance development. The widespread use of ACTs has considerably reduced malaria-related morbidity and mortality, and they remain an essential component of global malaria control operations.

3.4 Biosynthesis of Artemisinin

Artemisinin is produced in Artemisia annua glandular trichomes via a complicated process that includes mevalonate and isoprenoid metabolic routes.[16] The process starts with the production of isopentenyl pyrophosphate (IPP), a key precursor for terpenoid synthesis. IPP is transformed into farnesyl pyrophosphate (FPP) by a sequence of enzymatic processes, which is a critical intermediary in sesquiterpene biosynthesis.

The enzyme amorpha-4,11-diene synthase (ADS) catalyzes the first committed step in artemisinin biosynthesis, which is the cyclization of FPP to amorpha-4,11. This chemical then undergoes a series of oxidation processes catalyzed by cytochrome P450 monooxygenase (CYP71AV1), yielding artemisinic alcohol, artemisinic aldehyde, and artemisinic acid. These intermediates are important precursors in the metabolic route that leads to artemisinin synthesis.

Further enzymatic reduction and oxidation events convert artemisinic acid to dihydroartemisinic acid,

which is thought to be the immediate precursor of artemisinin. Unlike many natural compounds, the final conversion of dihydroartemisinic acid to artemisinin is thought to proceed via a series of spontaneous photooxidation and non-enzymatic processes in the presence of oxygen and light.

2qThis unique process produces the characteristic endoperoxide bridge that is responsible for artemisinin's antimalarial activity.

Understanding the biosynthesis of artemisinin has important implications for pharmaceutical manufacture and metabolic engineering. Biotechnology advancements have enabled the development of genetically modified microbes and enhanced plant varieties capable of producing larger artemisinin yields, thereby meeting the global demand for artemisinin-based antimalarial medicines.

3.5 Factors Affecting Artemisinin Content

Artemisinin concentration in Artemisia annua varies based on genetic, environmental, and agronomic factors.[17] Variations in plant genotype have an important role in determining artemisinin output, with different cultivars accumulating the substance in significantly different ways. Selective breeding and genetic improvement initiatives have thus been used to create high-yielding cultivars capable of producing larger amounts of artemisinin.

Temperature, light intensity, rainfall, altitude, and soil properties all have a substantial effect on artemisinin production. Adequate sunshine encourages the formation of glandular trichomes, which are the principal sources of artemisinin production. Temperature and photoperiod have a similar effect on plant growth, flowering behavior, and secondary metabolite accumulation. Unfavourable environmental circumstances may diminish biomass output, resulting in lower artemisinin content.

Agronomic methods like as planting density, irrigation, fertilization, harvest timing, and post-harvest processing all contribute to differences in artemisinin output. According to studies, the concentration of artemisinin peaks during the flowering stage of plant development. As a result, appropriate harvest timing is critical for achieving maximum yields and guaranteeing commercial cultivation's economic viability.

Biotechnology and cultivation techniques have advanced, allowing for increased artemisinin production through genetic engineering, tissue culture, elicitation methodologies, and metabolic pathway manipulation. Understanding the parameters that impact artemisinin accumulation is critical for increasing large-scale manufacturing and ensuring the long-term supply of this key antimalarial chemical.

4. PHARMACOLOGICAL ACTIVITIES OF ARTEMISININ

4.1 Antimalarial Activity

Artemisinin is a highly efficient natural substance for treating malaria.[18] The chemical works quickly against blood-stage Plasmodium parasites and is especially effective against Plasmodium falciparum, which is responsible for most severe malaria cases globally. Artemisinin is a key component of contemporary antimalarial therapy because to its ability to rapidly reduce parasite burden.

Artemisinin's antimalarial activity is principally due to the breakage of its endoperoxide bridge in the presence of iron from haemoglobin digestion in infected erythrocytes. This process produces extremely reactive free radicals, which damage critical parasite proteins, membranes, and metabolic pathways, eventually causing parasite death. Because of its unique method of action, artemisinin is effective against both drug-sensitive and drug-resistant Plasmodium strains.

Artemisinin reduces parasitaemia and clinical symptoms more quickly than other antimalarial medications. However, due to its short half-life, artemisinin is seldom used as a monotherapy. Instead, it is given in combination with longer-acting antimalarial drugs as part of artemisinin-based combination treatments (ACTs). These combinations improve treatment outcomes, lower the chance of recurrence, and delay the formation of resistance.

The use of ACTs has dramatically reduced malaria-related morbidity and mortality in endemic areas, and they have become an important component of global malaria control programs. Continuous research on artemisinin and its derivatives remains crucial to overcome developing resistance and ensure the long-term effectiveness of antimalarial treatment regimens.

4.2 Antioxidant Activity

Artemisinin is known for its antimalarial effects and antioxidant activity, which enhances its therapeutic potential.[10,19] Oxidative stress is caused by an imbalance between the creation of reactive oxygen species (ROS) and the body's antioxidant defence mechanisms. Excessive oxidative stress can damage cellular proteins, lipids, and nucleic acids, resulting in a variety of clinical diseases. Studies have shown that artemisinin and other phytochemicals found in Artemisia annua can neutralize free radicals and prevent oxidative damage.

Artemisinin's antioxidant properties originate from its ability to control cellular redox equilibrium and influence antioxidant enzyme systems. Artemisinin has been shown in experiments to increase the activity of natural antioxidant enzymes such superoxide dismutase, catalase, and glutathione peroxidase. It helps prevent cells from oxidative damage and maintains normal biological activities through these processes.

Artemisia annua's antioxidant activity is due in part to the presence of flavonoids, phenolic acids, and other secondary metabolites, as well as artemisinin. These chemicals may work together to scavenge free radicals and prevent oxidative reactions. Such interactions boost the plant's overall biological activity and add to its therapeutic potential.[10,19]

Artemisinin's antioxidant capabilities have piqued scientists' interest due to their possible significance in preventing or controlling oxidative stress-related disorders. Although further clinical studies are needed, existing evidence suggests that artemisinin may provide preventive advantages in addition to its antimalarial properties, broadening its pharmacological importance.

4.3 Anti-Inflammatory Activity

Artemisinin has shown anti-inflammatory properties in tests, suggesting its potential beyond antimalarial therapy.[20] Inflammation is a biological reaction that protects against infection or tissue harm; nevertheless, excessive or chronic inflammation can lead to the development of a variety of disorders. According to research, artemisinin can control inflammatory pathways and limit the generation of pro-inflammatory mediators that contribute to disease progression.

Artemisinin's anti-inflammatory benefits stem from its capacity to control immunological responses and inhibit inflammatory cytokines such TNF-α, IL-1β, and IL-6. Artemisinin has been shown to suppress the activation of NF-κB, a transcription factor that regulates the production of inflammatory genes. The chemical works through these ways to help minimize inflammation and tissue damage.

Several in vitro and in vivo investigations have shown that artemisinin is effective in treating inflammatory disorders. Its capacity to control immune cell function and reduce oxidative stress enhances its anti-inflammatory capabilities. These effects have sparked great interest in the possible use of artemisinin in the treatment of inflammatory and autoimmune illnesses.

The expanding body of evidence confirming artemisinin's anti-inflammatory properties emphasizes its broader therapeutic value. Further research may aid in the discovery of innovative therapeutic applications for artemisinin and its derivatives in disorders characterized by excessive inflammatory responses.

4.4 Anticancer Activity

Recent investigations show that artemisinin has promising anticancer effects against a variety of human cancers.[21] The molecule has been shown to suppress cancer cell growth and proliferation, making it a promising candidate for future oncological study. Unlike conventional chemotherapeutic medicines, artemisinin is selectively toxic to cancer cells while inflicting very little damage to normal cells, lowering the likelihood of side effects.

The anticancer effect of artemisinin is principally due to its endoperoxide bridge, which interacts with intracellular iron to produce reactive oxygen species and free radicals. Cancer cells have higher iron concentrations than normal cells, making them more vulnerable to oxidative damage caused by artemisinin. This mechanism causes cellular injury, mitochondrial malfunction, DNA damage, and cancer cell death.

In addition to causing apoptosis, artemisinin has been shown to reduce tumour angiogenesis, limit metastasis, and disrupt various signalling pathways involved in cancer growth. Experimental investigations have shown that it is effective against breast cancer, lung cancer, colorectal cancer, leukaemia, ovarian cancer, and a variety of other cancers. These data show that artemisinin could be an effective adjunct or lead molecule in cancer treatment.

Although most of the evidence currently comes from laboratory and preclinical studies, the increased interest in artemisinin-based anticancer research emphasizes its potential therapeutic value. Additional clinical trials are needed to determine its safety, efficacy, and potential relevance in future cancer therapy regimens.

4.5 Immunomodulatory Activity

Artemisinin and its derivatives have immunomodulatory characteristics that affect both innate and adaptive immune responses.[22] The immune system is responsible for protecting the body against infections and maintaining physiological balance. Immune function dysregulation has been linked to the development of autoimmune illnesses, chronic inflammatory disorders, and other pathological states. Artemisinin has been proven in studies to influence immune cell activity and inflammatory signalling pathways.

Artemisinin has been shown in studies to impact the proliferation and function of immune cells such as T lymphocytes, B lymphocytes, macrophages, and dendritic cells. It has been shown to decrease excessive immunological activation and lower pro-inflammatory cytokines while fostering a balanced immune response. These effects help to maintain immunological homeostasis and avoid tissue damage caused by uncontrolled inflammation.

Artemisinin's immunomodulatory function has sparked interest as a potential treatment for autoimmune and inflammatory illnesses. Experimental studies have revealed that it is useful in illnesses like rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Artemisinin, which regulates immune responses and reduces inflammatory mediators, may help alleviate illness symptoms and improve clinical outcomes.

Artemisinin's medicinal promise extends beyond malaria treatment, as evidence for its immunomodulatory effects grows. Further research is required to completely understand its mechanisms of action and to investigate its potential applications in immunological-mediated illnesses and other diseases requiring immune dysregulation.

5. MECHANISM OF ACTION OF ARTEMISININ

5.1 Activation of the Endoperoxide Bridge

Artemisinin's antimalarial effectiveness stems from a unique endoperoxide bridge in its chemical structure.[23] This peroxide linkage is required for the compound's biological activity and separates artemisinin from other antimalarial medicines. Artemisinin enters infected erythrocytes and encounters large quantities of iron produced by Plasmodium parasites during haemoglobin breakdown. The contact between iron and the endoperoxide bridge sets off a sequence of chemical events that activate the medication.

The cleavage of the endoperoxide bridge generates extremely reactive oxygen- and carbon-centered free radicals. These reactive intermediates assault parasite proteins, membrane structures, and cellular components, causing significant molecular damage. The rapid production of free radicals contributes to the potency and rapid action of artemisinin against malaria parasites.

Artemisinin's specific toxicity to infected red blood cells is mostly owing to the amount of iron within parasitized erythrocytes. Malaria parasites require a lot of haemoglobin to develop and survive; thus, they produce an environment that encourages artemisinin activation. As a result, the medicine is highly effective against the parasite while having minimal effects on normal host cells.

The activation of the endoperoxide bridge is a critical stage in artemisinin's mechanism of action and is responsible for its therapeutic efficacy. Understanding this process has greatly aided the development of artemisinin derivatives and combination medicines, which continue to play an important role in malaria therapy.

5.2 Generation of Reactive Oxygen Species

Artemisinin's antimalarial effect is mostly attributed to the production of highly reactive oxygen species (ROS) and free radicals after activating the endoperoxide bridge.[24]

These reactive molecules are formed when the peroxide bond reacts with ferrous iron found in infected erythrocytes.

The resultant oxidative stress creates a hostile intracellular environment that inhibits Plasmodium parasite survival and multiplication.

Artemisinin generates reactive oxygen species like as superoxide radicals, hydroxyl radicals, and other oxygen-derived intermediates that can cause significant cellular damage. These species interact with proteins, lipids, nucleic acids, and other important biomolecules found in the parasite. The accumulation of oxidative damage impairs crucial metabolic processes and jeopardizes the structural integrity of parasitic cells.

Unlike many traditional antimalarial drugs, which target specific biochemical pathways, artemisinin has a broad and diverse effect via ROS-mediated damage. This mechanism adds to its quick parasite-killing activity while decreasing the chance of immediate resistance development. Reactive oxygen species cause extensive molecular damage, which damages several cellular targets at the same time, making parasite life more difficult.

Artemisinin's antimalarial action is thus thought to rely heavily on the production of reactive oxygen species. This oxidative assault, together with other molecular interactions, eventually leads to parasite death and greatly contributes to the clinical efficacy of artemisinin-based therapy.

5.3 Parasite Protein and Membrane Damage

Artemisinin activation generates reactive intermediates that degrade critical proteins and membranes of Plasmodium parasites.[25] These free radicals easily interact with parasite biomolecules, causing structural changes and loss of normal cell function. As a result, key metabolic and physiological processes required for parasite survival are significantly disturbed.

Artemisinin-derived radicals have been found to alkylate a wide range of parasite proteins involved in metabolism, protein synthesis, cellular signalling, and stress response pathways. Damage to these proteins disrupts normal enzymatic action, reducing the parasite's capacity to maintain cellular homeostasis. The drug's rapid antimalarial action is due in part to its simultaneous targeting of several proteins.

In addition to protein degradation, artemisinin impairs parasite membrane integrity. Reactive oxygen species cause lipid peroxidation inside cellular and organelle membranes, which increases membrane permeability and structural instability. Damage to mitochondrial membranes, food vacuoles, and other intracellular structures further reduces parasite viability and speeds up cell death.

The simultaneous breakdown of proteins and membranes causes irreversible cellular damage and parasite eradication. This multi-target method of action is regarded as one of the primary causes of artemisinin and its derivatives' extraordinary efficacy against both sensitive and drug-resistant malaria parasites.

6. THERAPEUTIC APPLICATIONS OF ARTEMISININ

6.1 Treatment of Uncomplicated Malaria

Modern antimalarial therapy relies heavily on artemisinin and its variants for treating uncomplicated malaria. Fever, chills, headache, weariness, nausea, and sweating are symptoms of uncomplicated malaria, which does not involve significant organ malfunction or life-threatening consequences. Rapid and efficient therapy is required to halt illness progression and limit parasite transmission in the community.[26]

Artemisinin derivatives have rapid schizonticidal effect against the asexual blood stages of Plasmodium parasites. Following delivery, these medications reduce parasitaemia quickly, leading in rapid clinical improvement and symptom eradication. Their capacity to target both drug-sensitive and multidrug-resistant Plasmodium falciparum strains has greatly improved treatment outcomes in endemic areas.

Because of their short elimination half-life, artemisinin derivatives are rarely used alone. Instead, they are paired with longer-acting partner medications to form artemisinin-based combination treatments (ACT). This method improves therapeutic efficacy, lowers the chance of treatment failure, and reduces the likelihood of drug resistance. Artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine are among the most used ACT regimens.

The broad adoption of ACTs has significantly reduced malaria-related morbidity and mortality worldwide. Artemisinin derivatives have become first-line treatments for uncomplicated malaria in many endemic areas due to their efficacy, fast action, and good safety profile.[26]

6.2 Treatment of Severe Malaria

Cerebral malaria, severe anemia, acute respiratory distress syndrome, metabolic acidosis, renal failure, and multi-organ dysfunction are among the major complications of severe malaria, a potentially fatal medical illness. It mostly affects Plasmodium falciparum infections and necessitates prompt medical attention to lower the risk of death. Improving patient outcomes and halting the course of the disease depend on quick parasite elimination.[27]

Nowadays, the preferred medication for treating severe malaria is artesunate, a water-soluble derivative of artemisinin. It can be given intramuscularly or intravenously, enabling critically ill patients to quickly reach therapeutic medication concentrations. Artesunate has been shown to be more effective than quinine, to eliminate parasites more quickly, and to significantly lower mortality rates.[27]

The quick action of artesunate against circulating blood-stage parasites is the reason for its efficacy. The medication minimizes tissue damage and lowers the risk of serious consequences by rapidly lowering parasite density. To guarantee total parasite eradication and avoid recrudescence, patients are usually moved to a full course of oral artemisinin-based combination therapy after the initial parenteral treatment.

Clinical results for both adults and children with severe malaria have significantly improved since artesunate was introduced. Artemisinin derivatives' superior efficacy and safety profile have made them essential parts of contemporary malaria treatment plans and have greatly reduced the number of malaria-related fatalities globally.[27]

6.3 Artemisinin-Based Combination Therapies (ACTs)

For the treatment of simple Plasmodium falciparum malaria, artemisinin-based combination treatments (ACTs) are currently the most successful approach. ACTs provide quick parasite clearance while guaranteeing the eradication of leftover parasites by combining a longer-acting companion medication with a fast-acting artemisinin derivative. This combined strategy lowers the risk of developing resistance while improving treatment efficacy.

The complimentary pharmacological characteristics of the component medications provide the justification for ACTs. This combined effect lowers the chance of treatment failure and increases cure rates.[28]

In areas where malaria is endemic, several ACT regimens have been developed and are commonly utilized. Artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine, and dihydroartemisinin-piperaquine are examples of common combinations. Both drug-sensitive and multidrug-resistant strains of Plasmodium falciparum have been shown to be effectively combated by these combinations.

In many nations, the widespread use of ACTs has greatly reduced the morbidity and death associated with malaria. However, reports of delayed parasite clearance and the emergence of artemisinin resistance in some areas have brought attention to the significance of ongoing surveillance, prudent medication usage, and the creation of novel treatment approaches. ACTs continue to be the mainstay of contemporary malaria treatment and international malaria control initiatives despite these obstacles.[28]

7. SAFETY PROFILE AND ADVERSE EFFECTS OF ARTEMISININ

7.1 Common Adverse Effects

Artemisinin and its derivatives have a positive safety record when administered at authorized therapeutic doses.[29] Their widespread clinical use over several decades has shown a low incidence of significant adverse

events when compared to several standard antimalarial medicines. This good tolerability has played a crucial role in the success of artemisinin-based combination treatments in malaria treatment programs worldwide.

The most frequently reported adverse effects are minor and temporary in nature. Symptoms include nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness, exhaustion, and loss of appetite. In most situations, these symptoms are self-limiting and do not need termination of therapy. The frequency and severity of adverse effects may differ based on the artemisinin derivative used, the dosing regimen, and the patient features.[29]

Some patients may develop modest haematological or biochemical abnormalities during treatment, but these are usually reversible. Allergic reactions have been recorded seldom and typically present as skin rash, itching, or hypersensitivity responses. Compared to previous antimalarial drugs like quinine, artemisinin derivatives are associated with fewer serious treatment problems.

Artemisinin derivatives' overall safety and tolerability make them appropriate for treatment in a wide range of patient populations, including children and adults. Continued pharmacovigilance and clinical monitoring are critical for detecting rare adverse effects and ensuring the safe use of these medications in malaria treatment.

7.2 Toxicity and Safety Considerations

Although artemisinin derivatives are widely considered safe and effective antimalarial medicines, rigorous study of their toxicity profile is crucial for assuring their proper clinical use.[30] Extensive preclinical and clinical research have shown that these substances are relatively safe when supplied at the approved therapeutic levels. However, concerns about potential negative consequences from prolonged exposure, high-dose administration, or inappropriate use have been investigated.

Animal studies have found neurotoxic consequences at extremely high dosages of certain artemisinin derivatives, particularly artemether and arteether. These effects were most noticeable under experimental circumstances including sustained dosing and substantially higher exposure levels than those utilized in ordinary clinical practice. Clinically significant neurotoxicity has rarely been recorded in people, and artemisinin-based medicines continue to have a strong safety profile.[30]

The usage of artemisinin derivatives when pregnant has also been thoroughly researched. The available evidence suggests that these medications can be administered safely when the benefits outweigh the hazards, notably in the treatment of severe malaria, where quick action is required. Careful clinical monitoring is still indicated during pregnancy and in patients with underlying medical problems.

Overall, the therapeutic benefits of artemisinin and its derivatives much outweigh any dangers associated with treatment. Continued pharmacovigilance, adequate dose, and reasonable use of artemisinin-based medicines are critical to maintaining their favourable safety profile and guaranteeing effective malaria treatment.

8. CURRENT CHALLENGES AND FUTURE PERSPECTIVES

8.1 Artemisinin Resistance

Artemisinin resistance is a key concern for worldwide malaria control efforts.[31] Although artemisinin-based combination therapies (ACTs) continue to be highly effective in many endemic areas, reports of delayed parasite clearance have raised questions about the treatments' long-term durability. Resistance has been predominantly linked to changes in the Plasmodium falciparum kelch13 (pfk13) gene, which impair parasite susceptibility to artemisinin and limit treatment efficacy.

When ACTs are delivered correctly, artemisinin resistance seldom results in complete therapy failure; nonetheless, it can cause slower parasite clearance and increase the probability of resistance developing against companion medicines. This condition jeopardizes the efficacy of present treatment regimens and may jeopardize decades of progress in malaria control and elimination projects. The spread of resistant parasite strains to new geographical regions is still a serious public health problem.[31]

Several factors contribute to the development and spread of resistance, including improper drug usage, poor treatment adherence, inferior medications, and widespread antimalarial drug use. Continuous surveillance and molecular monitoring are thus required for early detection of resistant strains and to guide treatment strategies. Resistance management strategies rely heavily on strengthening healthcare systems and promoting responsible drug use.

Addressing artemisinin resistance involves a global collaboration of researchers, healthcare professionals, policymakers, and public health groups. Continued investment in drug development, resistance surveillance, and new treatment techniques will be critical to maintaining the efficacy of artemisinin-based medicines and advancing malaria control.[31]

8.2 Future Research Directions

Artemisinin has shown effective in treating malaria, but more study is needed to overcome new difficulties and maximize its therapeutic potential.[32] The advent of artemisinin-resistant Plasmodium strains has emphasized the critical need for the development of new antimalarial drugs, enhanced combination regimens, and novel treatment techniques. Future research should focus on identifying novel therapeutic targets and developing

molecules that can overcome resistance while maintaining high efficacy and safety.

Biotechnology and metabolic engineering advancements provide intriguing potential to improve artemisinin production. Genetic modification of Artemisia annua, optimization of growing procedures, and microbial biosynthetic approaches have the potential to increase artemisinin productivity and provide a continuous supply of the medication. These advancements may lower production costs and increase accessibility in malaria-endemic areas.[32]

In addition to antimalarial activity, artemisinin has been shown to have antioxidant, anti-inflammatory, anticancer, antiviral, and immunomodulating activities. Further preclinical and clinical research is needed to properly investigate these pharmacological properties and assess their therapeutic utility. Understanding the molecular processes underlying these effects could aid in the discovery of new uses for artemisinin and its derivatives in a variety of disorders.

Future research should focus on pharmacovigilance, resistance surveillance, and the appropriate use of artemisinin-based medicines. Collaborative efforts among researchers, healthcare professionals, pharmaceutical companies, and public health organizations will be critical for maximizing artemisinin's therapeutic effects and aiding worldwide malaria eradication efforts.[32]

9. FINDINGS AND DISCUSSION

The current study emphasizes the importance of Artemisia annua and its main bioactive component, artemisinin, in malaria prevention and therapy. Artemisinin has emerged as one of the most effective antimalarial drugs, thanks to its quick parasite-killing activity and efficacy against drug-resistant Plasmodium strains. According to the review, artemisinin's powerful mechanism of action is due to its unusual chemical structure, specifically its endoperoxide bridge. In addition to its antimalarial capabilities, artemisinin has a variety of pharmacological activities, including antioxidant, anti-inflammatory, anticancer, and immunomodulatory effects, indicating a broad therapeutic potential.

The invention of artemisinin derivatives and artemisinin-based combination medicines has greatly improved malaria treatment outcomes and contributed to worldwide malaria control initiatives. However, the emergence of artemisinin resistance and the requirement for long-term manufacturing remain significant concerns. Overall, the findings highlight the significance of ongoing research on artemisinin, its derivatives, and enhanced therapeutic techniques to boost efficacy, overcome resistance, and broaden its applications in modern medicine.

10. CONCLUSION

Artemisinin, discovered from Artemisia annua L., is one of the most important discoveries in the history of antimalarial drug research. The chemical has altered malaria treatment by exerting rapid and robust activity against Plasmodium parasites, even drug-resistant forms. Its unique endoperoxide bridge and specific mechanism of action have contributed to its outstanding therapeutic efficacy, cementing artemisinin-based combination therapies as the foundation of current malaria management.

Aside from its antimalarial activity, artemisinin has a variety of pharmacological properties, including antioxidant, anti-inflammatory, anticancer, and immunomodulatory activities. These various biological effects have sparked significant scientific interest and broadened the area of study on artemisinin and its derivatives. Advances in phytochemical, pharmacological, and biotechnological studies have further advanced understanding of the substance and supported its continued medicinal use.

Despite its success, issues such as growing artemisinin resistance, production restrictions, and the requirement for long-term medication supply remain major problems. Continued research into novel therapeutic techniques, improved production technologies, resistance monitoring, and wider clinical applications will be critical to ensuring the long-term efficacy of artemisinin-based medicines.

To summarize, artemisinin remains a useful natural-product-derived antimalarial drug and an outstanding example of medicinal plants' contribution to modern medicine. Ongoing scientific advances are likely to improve its significance in worldwide malaria control and potentially broaden its applicability to other therapeutic areas in the future.[33]

REFERENCES

1. White NJ. Antimalarial drug resistance. *J Clin Invest*, 2004; 113(8): 1084–1092.
2. Cox FEG. History of the discovery of the malaria parasites and their vectors. *Parasit Vectors*, 2010; 3: 5.
3. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. *Nat Rev Immunol*, 2005; 5(9): 722–735.
4. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. *Lancet Infect Dis*, 2004; 4(6): 327–336.
5. Sachs J, Malaney P. The economic and social burden of malaria. *Nature*, 2002; 415(6872): 680–685.
6. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. *Malar J*, 2011; 10: 144.
7. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant

malaria. *Lancet Infect Dis*, 2002; 2(4): 209–218.
8. Wells TNC, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. *Nat Rev Drug Discov*, 2009; 8(11): 879–891.
9. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. *Science*. 1985; 228(4703): 1049–1055.
10. Ferreira JFS, Luthria DL, Sasaki T, Heyerick A. Flavonoids from *Artemisia annua* L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. *Molecules*, 2010; 15(5): 3135–3170.
11. Duke SO, Paul RN. Development and fine structure of the glandular trichomes of *Artemisia annua* L. *Int J Plant Sci*. 1993; 154(1): 107–118.
12. Ferreira JFS, Simon JE, Janick J. Developmental studies of artemisinin production in *Artemisia annua* L. *HortScience*. 1995; 30(3): 635–637.
13. Bhakuni RS, Jain DC, Sharma RP, Kumar S. Secondary metabolites of *Artemisia annua* and their biological activity. *Curr Sci*, 2001; 80(1): 35–48.
14. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. *Int J Parasitol*, 2002; 32(13): 1655–1660.
15. Haynes RK. Artemisinin and derivatives: the future for malaria treatment? *Curr Opin Infect Dis*, 2001; 14(6): 719–726.
16. Towler MJ, Weathers PJ. Evidence of artemisinin production from IPP stemming from both the mevalonate and the nonmevalonate pathways. *Plant Cell Rep*, 2007; 26(12): 2129–2136.
17. Ferreira JFS, Janick J. Floral morphology of *Artemisia annua* with special reference to trichomes. *Int J Plant Sci*. 1995; 156(6): 807–815.
18. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. *Drug Resist Updat*, 2004; 7(4–5): 233–244.
19. Brown GD. The biosynthesis of artemisinin (Qinghaosu) and the phytochemistry of *Artemisia annua* L. (Qinghao). *Molecules*, 2010; 15(11): 7603–7698.
20. Efferth T. Beyond malaria: the inhibition of viruses by artemisinin-type compounds. *Biotechnol Adv*, 2018; 36(6): 1730–1737.
21. Efferth T. From ancient herb to modern drug: artemisinin as a novel anti-cancer therapy. *Semin Cancer Biol*, 2017; 46: 65–83.
22. Efferth T, Oesch F. The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. *Med Res Rev*, 2021; 41(6): 3023–3061.
23. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin—the debate continues. *Molecules*, 2010; 15(3): 1705–1721.
24. Meshnick SR. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. *Microbiol Rev*. 1996; 60(2): 301–315.
25. Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in *Plasmodium falciparum*. *Nat Commun*, 2015; 6: 10111.
26. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. *Am J Trop Med Hyg*, 2007; 77(6 Suppl): 181–192.
27. Dondorp AM, Nosten F, Stepniewska K, Day N, White NJ. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet*, 2005; 366(9487): 717–725.
28. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. *Nat Rev Microbiol*, 2009; 7(12): 864–874.
29. Price R, van Vugt M, Nosten F, Luxemburger C, Brockman A, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. *Am J Trop Med Hyg*. 1999; 60(4): 547–555.
30. Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S, White NJ. Neuropathologic toxicity of artemisinin derivatives in a mouse model. *Am J Trop Med Hyg*, 2002; 67(4): 423–429.
31. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*, 2014; 371(5): 411–423.
32. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. *Nature*, 2013; 496(7446): 528–532.
33. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nat Med*, 2011; 17(10): 1217–1220.